MPG.eBooks - Search Results - ("positivism" OR "positivity")

1

Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) : indication: indicated in addition to standard therapy for reducing disease activity in adult patients...

Published 2020

CADTH

“..., autoantibody-positive SLE. This submission relates to belimumab subcutaneous (SC) injection, 200 mg/mL weekly...”

Read Now

2

Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) : indication: indicated in addition to standard therapy for reducing disease activity in adult patients...

Published 2020

CADTH

“..., autoantibody-positive SLE. This submission relates to belimumab subcutaneous (SC) injection, 200 mg/mL weekly...”

Read Now

3

Clinical review report: Satralizumab (Enspryng) : (Hoffmann-La Roche Limited) : indication neuromyelitis optica spectrum disorder

Published 2021

Canadian Agency for Drugs and Technologies in Health

“... of NMOSD in adult and adolescent patients who are AQP4 antibody positive...”

Read Now

4

Clinical review report: Eculizumab (Soliris) : Alexion Pharma Canada Corp. : indication: neuromyelitis optica spectrum disorder

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... disorder in adult patients who are anti-aquaporin-4 antibody positive...”

Read Now

5

CADTH reimbursement recommendation: Satralizumab (Enspryng) : for the treatment of neuromyelitis optica spectrum disorder : recommendation : reimburse with conditions

Published 2021

Canadian Agency for Drugs and Technologies in Health

“... years and older, anti-AQP4 positive, have had at least 1 NMOSD relapse in the 12 months before...”

Read Now

6

Clinical review report: Eculizumab (Soliris) : Alexion Pharma Canada corporation : indication : adult patients with generalized myasthenia gravis

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... effects of eculizumab for the treatment of adult patients who are AChR-antibody-positive and have...”

Read Now

7

CADTH Canadian Drug Expert Committee recommendation: Eculizumab (Soliris - Alexion Pharma Canada Corp.) : indication : the treatment of neuromyelitis optica spectrum disorder (NMOS...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“...-AQP4 antibody positive. Eculizumab is not intended for acute treatment of an NMOSD relapse. Eculizumab...”

Read Now

8

Pharmacoeconomic report: Eculizumab (Soliris) : Alexion Pharma Canada Corporation : indication : adult patients with generalized myasthenia gravis

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... for patients with refractory AChR-antibody-positive generalized myasthenia gravis (gMG) at a willingness-to-pay...”

Narrow Search